Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. In Onkológia. ISSN 1336-8176. Bratislava : SOLEN, 2015, 2015, roč. 10, č. 1, s. 60.